Table 1.
Baseline characteristics according to plasma IGF-I and IGFBP-3 (N = 527)
IGF-I (quartiles) |
IGFBP-3 (quartiles) |
|||||||
---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | |
Median age, y | 64 | 60 | 61 | 58 | 63 | 63 | 58 | 59 |
Median BMI, kg/m2 | 25.3 | 25.4 | 26.5 | 27.1 | 25.5 | 26.5 | 25.9 | 27.1 |
Male (%) | 39 | 50 | 70 | 76 | 63 | 56 | 66 | 49 |
ECOG PS = 2 (%) | 11 | 2 | 3 | 2 | 7 | 7 | 2 | 2 |
Treatment arm (%) | ||||||||
IFL | 22 | 25 | 23 | 19 | 27 | 20 | 18 | 23 |
FOLFOX4 | 52 | 56 | 60 | 63 | 52 | 62 | 61 | 57 |
IROX | 26 | 19 | 17 | 18 | 21 | 18 | 21 | 20 |
Race (%) | ||||||||
White | 89 | 86 | 86 | 83 | 89 | 84 | 84 | 87 |
Non-white | 11 | 14 | 14 | 17 | 11 | 16 | 16 | 13 |
Abbreviations: kg/m2, kilograms per meters squared; ECOG PS, Eastern Cooperative Oncology Group performance status; IFL, bolus irinotecan, 5-FU, and leucovorin; FOLFOX4, infusional 5-FU, leucovorin, and oxaliplatin; IROX, irinotecan and oxaliplatin.